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Abstract
Background: The National Institutes of Health (NIH) Health Care Systems Research Collaboratory (NIH
Collaboratory) seeks to produce generalizable knowledge about the conduct of pragmatic research in health
systems. This analysis applied the PRECIS-2 pragmatic trial criteria to five NIH Collaboratory pragmatic trials to better
understand 1) the pragmatic aspects of the design and implementation of treatments delivered in real world
settings and 2) the usability of the PRECIS-2 criteria for assessing pragmatic features across studies and across time.
Methods/Design: Using the PRECIS-2 criteria, five pragmatic trials were each rated by eight raters. For each trial,
we reviewed the original grant application and a required progress report written at the end of a 1-year planning
period that included changes to the protocol or implementation approach. We calculated median scores and
interrater reliability for each PRECIS domain and for the overall trial at both time points, as well as the differences in
scores between the two time points. We also reviewed the rater comments associated with the scores.
Results: All five trials were rated to be more pragmatic than explanatory, with comments indicating that raters
generally perceived them to closely mirror routine clinical care across multiple domains. The PRECIS-2 domains for
which the trials were, on average, rated as most pragmatic on the 1 to 5 scale at the conclusion of the planning
period included primary analysis (mean = 4.7 (range = 4.5 to 4.9)), recruitment (4.3 (3.6 to 4.8)), eligibility (4.1 (3.4 to
4.8)), setting (4.1 (4.0 to 4.4)), follow-up (4.1 (3.4 to 4.9)), and primary outcome (4.1 (3.5 to 4.9)). On average, the less
pragmatic domains were organization (3.3 (2.6 to 4.4)), flexibility of intervention delivery (3.5 (2.1-4.5)), and flexibility
of intervention adherence (3.8 (2.8-4.5)). Interrater agreement was modest but statistically significant for four trials
(Gwet’s AC1 statistic range 0.23 to 0.40) and the intraclass correlation coefficient ranged from 0.05 to 0.31. Rating
challenges included assigning a single score for domains that may relate to both patients and care settings (that is,
eligibility or recruitment) and determining to what extent aspects of complex research interventions differ from
usual care.
Conclusions: These five trials in diverse healthcare settings were rated as highly pragmatic using the PRECIS-2
criteria. Applying the tool generated insightful discussion about real-world design decisions but also highlighted
challenges using the tool. PRECIS-2 raters would benefit from additional guidance about how to rate the
interwoven patient and practice-level considerations that arise in pragmatic trials.
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Background
Pragmatic clinical trials are “primarily designed to deter-
mine the effects of an intervention under the usual con-
ditions in which it will be applied”; they contrast with
explanatory trials which “are primarily designed to deter-
mine the effects of an intervention under ideal circum-
stances” [1]. The United States (U.S.) National Institutes
of Health (NIH) Healthcare Systems Research Collabora-
tory (the NIH Collaboratory) was established to advance
large-scale pragmatic clinical trials through the conduct
of pragmatic trial demonstration projects. These demon-
stration projects are being performed in large and di-
verse healthcare settings around the United States and
allow exploration of best practices for appropriately de-
signing pragmatic trials in addition to generating trial
findings [2]. Each trial had a design phase for 1 year and
a subsequent implementation phase if approved after a
preliminary report. The NIH Collaboratory comprises
the research teams that design and perform the individ-
ual trials; a coordinating center with expertise in design,
biostatistics, bioethics, and electronic health data; and
NIH scientists.
The purpose of this analysis was to measure the de-
gree to which the NIH Collaboratory trials are pragmatic
at both the design and implementation phases using a
version of the Pragmatic Explanatory Continuum Indica-
tor Summary framework (PRECIS-2) [3]. In addition, be-
cause all NIH Collaboratory trials begin with a yearlong
planning phase to pilot test the intervention and evalu-
ate feasibility of aspects such as outcome ascertainment
methods and integration with workflow, we were able to
study whether and how trial design changed from
conceptualization to implementation. As a secondary
goal, we sought to assess the usability of PRECIS-2 as a




The individual NIH Collaboratory Trials were approved
by the relevant research ethics boards. This analysis did
not require informed consent from raters nor ethical ap-
proval because the data sources were limited to the
study protocols, not information about human subjects.
In addition, all raters were co-authors of the paper ra-
ther than subjects of the research.
Setting
The U.S. NIH is the largest medical research agency in
the world. Through funding from the NIH, the NIH Col-
laboratory seeks “to strengthen the national capacity to
implement cost-effective large-scale research studies that
engage health care delivery organizations as research
partners. The aim of the program is to provide a
framework of implementation methods and best prac-
tices that will enable the participation of many health
care systems in clinical research” [4]. The NIH Colla-
boratory funded five pragmatic clinical trials at both a
planning and implementation phase in 2012 and 2013,
respectively. These trials are described in Table 1 and in-
clude 1) Active Bathing to Eliminate (ABATE) Infection,
2) Lumbar Image Reporting with Epidemiology (LIRE),
3) Collaborative Care for Chronic Pain in Primary Care
(PPACT), 4) Strategies and Opportunities to Stop Colo-
rectal Cancer (STOP CRC), and 5) Time to Reduce
Mortality in End-Stage Renal Disease (TiME). Although
additional trials have been funded through the Colla-
boratory, they are not included in this analyses as they
had not been awarded funding for the implementation
phase until completion of the analyses.
Participants/Raters
Raters were trial principal investigators (PIs) or other in-
vestigators from their team (n = 4), Coordinating Center
staff (1), or NIH staff (6). Six of the raters had familiarity
with all five trials either because they had participated in
funding decisions or regular cross-project meetings.
Two raters (both NIH staff ) had limited knowledge of
any of the projects prior to participating in the PRECIS
2 exercise. Raters were recruited based on their interest
and availability. The six NIH staff rated all five trials.
The PIs or other investigators, as well as the Coordinat-
ing Center staff, each rated only two trials, one of which
was his/her own.
Rating procedures
To measure the pragmatic nature of the NIH Collabora-
tory trials, we used the PRECIS-2 toolkit (https://
crs.dundee.ac.uk/precis). The CONSORT workgroup on
Pragmatic Trials created the PRECIS criteria to help tri-
alists design trials that are pragmatic across multiple do-
mains [1, 5]. While not primarily intended to analyze
trials post hoc, the original PRECIS scale was success-
fully used for this purpose [5]. Based on findings from
the initial use of the tool, a team at the University of
Dundee developed the second version [6], which reduces
the number of domains rated from 10 to nine, makes
comparisons to usual care without explicit rating of the
control conditions, and considers external validity in the
recruitment and setting domains.
The PRECIS-2 toolkit includes nine domains: (1) eligi-
bility - who is selected to participate in the trial; (2) re-
cruitment - how participants are recruited into the trial;
(3) setting - where the trial is being done; (4)
organization - what expertise and resources are needed
to deliver the intervention; (5) delivery flexibility - how
the intervention is delivered; (6) adherence flexibility -
what measures are in place to make sure participants
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Table 1 Summary of included projects






Does routine daily bathing with
antiseptic soap for all patients plus
targeted use of a nasal antibiotic
ointment for MRSA carriers reduce
multidrug resistant organisms and
bloodstream infections in general




Inpatients in non-critical care
units at 53 U.S. HCA hospitals.
Units where chlorhexidine
bathing or nasal decolonization
is common were excluded.
Cluster randomized trial of hospitals
to compare two quality
improvement strategies to reduce
multidrug resistant organisms and
bloodstream infections in non-critical
care units. The two strategies to be
evaluated are:
No changes of note.
Arm 1: Routine Care - Routine policy
for showering/bathing
Arm 2: Decolonization - Use of
chlorhexidine as routine soap for
showering or bed bathing for all
patients plus mupirocin × 5 days if







benchmark data to spine imaging
reports decrease subsequent
back-related healthcare utilization?




Clinic Health System, and
Henry Ford Health System
Approximately 150,000 adults
for whom a primary care
provider has requested
imaging of the lumbar spine
Cluster randomized trial comparing
typical imaging reports to those that
include benchmarks prevalence data
of findings in patients without back
pain.









team-based program sited in
primary care help patients
manage chronic pain?
Primary practices in three
Kaiser Permanente regions
Approximately 1,000 patients
prioritized by their providers
who have nonmalignant chronic




services within the primary care
setting to usual care. The
intervention is an integrated,
interdisciplinary program that guides
all pain-related care for intervention
patients. It is embedded into
everyday clinical practice flow
utilizing assessment measures and
intervention staff directly from the
clinical care system.










Does an evidence-based, culturally
tailored approach increase
colorectal cancer screening in




30,000 patients aged 50 to 74
with no evidence of having had
a recent colorectal cancer
screening exam (fecal test,
sigmoidoscopy or colonoscopy),
and no history of colorectal
disease.
Cluster randomized trial comparing
usual care to intervention. The
intervention consists of an
automated data-driven, electronic
health record-linked program for
mailing FIT kits (with linguistically ap
propriate pictographic instructions
and return postage) to patients due
for CRC screening.
STOP CRC allowed patient
reminders to be sent by











a hemodialysis session duration of
at least 4.25 hours improve survival,
reduce hospitalizations and improve
Two large dialysis
provider organizations
6432 patients with end stage




clinical trial for patients initiating
treatment with maintenance
hemodialysis. Facilities are
randomized in a 1:1 distribution to
24 hour urine collection
eliminated and the quality of
life survey was changed to
the survey administered as









Table 1 Summary of included projects (Continued)
quality of life for patients with
end-stage kidney disease?
either:Intervention arm: recommend
dialysis session durations of at least 4.25
hours for all patients initiating hemodialysis
treatment regardless of body size or
dialysis solute clearance measurements,










adhere to the intervention; (7) follow-up - how closely
participants are followed-up; (8) primary outcome - how
relevant is it to participants; and (9) primary analysis -
to what extent all data all included. Each domain is
scored on a five-point Likert scale from very explanatory
(1) to very pragmatic (5), with a score of 3 indicating
that a trial is equally pragmatic and explanatory. In
addition, an overall composite score is reported for a
given trial to characterize the overall pragmatic nature
of the trial. We also calculated an overall mean score for
each domain across trials, to illustrate for which do-
mains the trials, in general, were more or less pragmatic.
Training
All raters received training in applying PRECIS-2. The
training consisted of an orientation webinar by one au-
thor (RG) based on the PRECIS-2 toolkit, practice with
a published protocol, and a second web conference to
calibrate ratings by discussing ratings that differed
among the individuals participating in the training. Fol-
lowing the training, each of the five demonstration pro-
jects was rated by eight raters and evaluated at two time
points, using the initial grant application and a required
progress report written at the end of a 1-year planning
period that included changes to the protocol or imple-
mentation approach. Four trials included a rating by a
trial team member. Each rater entered their two sets of
ratings on a form, which included space for comments.
Analysis
We produced one PRECIS wheel for each time point
(pilot/planning phase and implementation phase) for
each of the five trials using the PRECIS-2 Toolkit, which
calculates the median scores for ratings for a given trial.
The data were analyzed using STATA 12.0 (StataCorp,
College Station, TX, US) and SAS 9.3. We calculated the
mean and median scores and the range of scores for
each domain, trial, and time point. We also calculated
the differences in scores between the two time points for
each of the PRECIS-2 domains for each trial. To evalu-
ate change over time, we examined the spread in these
differences and determined the level of statistical signifi-
cance (for a given domain for a given trial) using the
sign test in Stata 12.0, a Wilcoxon nonparametric test of
equality of matched pairs. Interrater agreement or reli-
ability was calculated for each trial using Gwet’s AC1
statistic [7], a more robust version [8] of Fleiss’ Kappa
[9]. Interrater agreement was also measured using the
intraclass correlation coefficient. Additionally, we ob-
tained each trial principal investigator’s impressions on
the degree of congruence of the ratings with on-the-
ground experience.
To inform our secondary goal of assessing PRECIS-2
usability, we reviewed the comments provided by the
raters for each trial. Two authors (KJ and GN) organized
the comments by domain and indicated study design as-
pects that raters considered in their scoring that were
not specified in the PRECIS-2 toolkit, as well as rating
challenges. All raters reviewed these results.
Results
Comparison of domains across trials
All five demonstration projects were rated to be more
pragmatic than explanatory. The overall composite
scores, calculated on the basis of the average score of
the means and medians across the domains, are all
greater than 3 on a scale where 3 signifies equally
pragmatic/explanatory. Mean and median scores for
each trial at the implementation phase for each do-
main are presented in Table 2. Whereas all five trials
were more pragmatic than explanatory (that is, overall
composite median rating > 3.0), TiME and LIRE were
found to be the most pragmatic (4.5 overall compos-
ite median rating for both). The domains for which
those two trials were most pragmatic (that is, mean
of eight raters > 4.5) were recruitment (mean of eight
raters = 4.8) and follow-up (4.9) for LIRE, and eligibil-
ity (4.8), recruitment (4.6), follow-up (4.6), and pri-
mary outcome (4.9) for TiME. The domains for
which they were less pragmatic but were still more
pragmatic than explanatory (that is, mean of eight
raters < 4.5 but > 3.0), were organization (3.8), setting
(4.0), primary outcome (3.6), and eligibility (4.3) for
LIRE and delivery (4.1), setting (4.4), organization
(4.4), and adherence (4.4) for TiME. The trials that
were less pragmatic but still more pragmatic than ex-
planatory were ABATE and PPACT (overall compos-
ite median rating = 3.5 and 3.6, respectively.) The
domains that were rated as more explanatory than
pragmatic (that is, mean of eight raters < 3.0) were
organization (2.6) and delivery (2.1) for ABATE and
organization (2.9) and adherence (2.8) for PPACT.
However, those two trials were also found to be very
pragmatic (that is, mean of eight raters > 4) on several
dimensions including recruitment (4.5) and analysis
(4.5) for ABATE and primary outcome (4.6) and ana-
lysis (4.9) for PPACT. STOP CRC fell in between,
with an overall composite median rating of 3.9. In
general, the domains along which trials were, on
average, most pragmatic included primary analysis
(mean = 4.7 range = 4.5 to 4.9)), recruitment (4.3 (3.6
to 4.8)), eligibility (4.1 (3.4 to 4.8)), setting (4.1 (4.0
to 4.4)), follow-up (4.1 (3.4 to 4.9)), and primary out-
come (4.1 (3.5 to 4.9)). On average, the less prag-
matic, although still more pragmatic than explanatory,
the domains were organization (3.3 (2.6 to 4.4)), flexi-
bility of delivery (3.5 (2.1 to 4.5)), and flexibility of
adherence (3.8 (2.8 to 4.5)).
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Reliability
At the implementation phase, we found modest but
statistically significant interrater agreement for four of
the five trials (AC1 statistic ranged from 0.23 to 0.40, p
values ≤ 0.001; Table 2). Intraclass correlation coeffi-
cients ranged from 0.05 to 0.31. Ratings for the planning
phase were similar: AC1 statistics ranged from 0.11 to
0.44 and all p values were ≤ 0.001 (data not shown). We
examined outliers to see if differences existed among
raters who were and were not previously familiar with
the studies or for raters who were rating their own pro-
ject. We did not observe any notable patterns. However,
the principal investigators’ on-the-ground experience did
not always match the rater-assessed examples of change,
as discussed further below.
Change over time
Trial refinements over the course of the planning phase
represented responses to logistical issues, stakeholder
preferences, and input from the NIH Collaboratory
members as the studies approached full implementation.
Some examples are shown in Table 1. Figure 1 shows
the PRECIS wheels for each of the five trials at the two
time points. We found between one and three rater-
assessed significant changes over time for each study;
however, we did not note any consistency in terms of
direction or domain. Additionally, the PIs agreed with
the direction of the ratings for only one study. As an ex-
ample, raters assessed that recruitment procedures be-
came more pragmatic for one study, but the PI indicated
that the story was more complex, with some aspects
becoming more pragmatic but others less so. Study
procedures were refined such that organizational ap-
proaches to patient prioritization did indeed more
closely mirror everyday clinical care; however, the timing
of patients receiving the intervention became more tied
to study-specific provider randomization points.
Rater comments
Table 3 summarizes factors that raters noted they had
considered in rating the study. These were largely con-
sistent with the examples in the PRECIS-2 toolkit that
were included in the training materials. However, the
raters’ comments about additional considerations that
they factored into assigning domain ratings highlight
that the PRECIS-2 ratings are not necessarily conclusive
but generate a starting point for discussion, as we de-
scribe in more detail below.
Raters noted several challenges in applying the criteria
in their commentary. For the eligibility domain, raters
had to consider both eligibility of the facility and eligibil-
ity of the patient. For example, for most of the trials,
participating facilities or clinics were selected by
convenience and no information was available about in-
clusion criteria even though this was the unit of
randomization. Facility willingness to participate was
viewed by raters as an aspect of eligibility that was more
explanatory than pragmatic.
The setting and organization domains proved particu-
larly difficult to rate relative to usual care. Raters com-
mented that there are many different aspects to consider
when rating settings within the diverse U.S. health
Table 2 PRECIS scores by trial (at implementation phase) and domain
PRECIS domain ABATE Infection LIRE PPACT STOP CRC TiME
Mean (SD, Median) Mean (SD, Median) Mean (SD, Median) Mean (SD, Median) Mean (SD, Median)
Eligibility 3.9 (1.1, 4.0) 4.3 (0.9, 4.5) 3.4 (1.1, 3.5) 4.4 (0.5, 4.0) 4.8 (0.7, 5.0)
Recruitment 4.5 (1.1, 5.0) 4.8 (0.5, 5.0) 3.6 (0.9, 4.0) 3.9 (0.8, 4.0) 4.6 (0.7, 5.0)
Setting 4.0 (1.1, 4.0) 4.0 (0.9, 4.0) 4.0 (1.1, 4.0) 4.3 (0.7, 4.0) 4.4 (0.7, 4.5)
Organization 2.6 (1.2, 2.5) 3.8 (0.9, 3.5) 2.9 (0.8, 3.0) 2.9 (0.8, 3.0) 4.4 (1.1, 5.0)
Delivery 2.1 (1.0, 2.0) 4.5 (0.8, 5.0) 3.0 (0.5, 3.0) 3.8 (0.5, 4.0) 4.1 (0.6, 4.0)
Adherence 3.4 (1.4, 3.5) 4.5 (0.8, 5.0) 2.8 (0.7, 3.0) 3.8 (0.9, 3.5) 4.4 (0.7, 4.5)
Follow-up intensity 3.4 (1.2, 3.0) 4.9 (0.4, 5.0) 3.9 (0.6, 4.0) 3.9 (0.8, 4.0) 4.6 (0.5, 5.0)
Primary outcome 3.5 (1.1, 3.0) 3.6 (0.9, 4.0) 4.6 (0.5, 5.0) 3.9 (1.1, 4.0) 4.9 (0.4, 5.0)
Analysis 4.5 (0.8, 5.0) 4.5 (0.5, 4.5) 4.9 (0.4, 5.0) 4.9 (0.4, 5.0) 4.5 (0.8, 5.0)
Overall composite
Median rating 3.5 4.5 3.6 3.9 4.5
Mean rating 3.5 4.3 3.7 4.0 4.5
AC1 statistic 0.08 0.29* 0.23* 0.28* 0.40*
Intraclass correlation coefficient 0.31 0.07 0.06 0.05 0.06
Note: Overall ratings are average scores
*p value ≤ 0.001
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system, including geography, types of care provided, and
financing (for example, fee for service versus managed
care). Furthermore, institutions where these trials were
occurring all had the resources and infrastructure to
support a systems-change intervention, making it
possible that these institutions had relatively high
organizational resources to support complex quality im-
provement. Even if this infrastructure was not research-
specific, this potential difference from usual care led to
more explanatory ratings of the setting and organization
domains.
For the flexibility of delivery domain, the determin-
ation of whether an intervention was relatively more re-
strictive than a strict quality control protocol in usual
care was challenging. Similarly, it was challenging to rate
the flexibility of adherence for an intervention relative to
usual care because, if the intervention was successful,
the adherence procedures could become usual care. Sec-
ond, few studies documented extensively efforts under-
taken to maintain “adherence” at the organizational
level. For example, when leadership changes occur, the
need arises for substantial discussion and planning to
continually “engage” the stakeholders/leadership in the
health system. Most of these activities are not planned
but are undertaken ad hoc when health systems lose
their leadership. To what extent these efforts to re-
engage leadership in the conduct of the trial represented
less pragmatic adherence is unclear.
Primary outcome is rated according to the extent to
which it is relevant to participants, but raters struggled
with how to rate outcomes that might be more import-
ant to health systems than to patients, for example,
process efficiency. Raters also had to determine how to
factor in criteria that pertained to multiple domains, and
whether they should “be counted” more than once. For
example, consent by patients or organizational willing-
ness to participate pertained to multiple domains: eligi-
bility, recruitment, setting. Thus, some raters attempted
to provide an average score across unrelated subdo-
mains; other raters may have only considered a single
subdomain.
Discussion
The objective of this study was to analyze five prag-
matic trials in order to characterize pragmatic versus
explanatory design by PRECIS-2 domains and how
design details changed over the course of a yearlong
study-planning period. In five trials designed as prag-
matic trials in diverse U.S. healthcare settings, we
observed that trials were designed as more pragmatic
than explanatory as measured by all PRECIS-2
domains.
Fig. 1 PRECIS wheels as assessed by raters for each of the five trials at two time points. Ratings on a 1 – 5 scale indicate more explanatory to
more pragmatic ratings. The dashed line indicates the planning phase. The solid line indicates the implementation phase
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Table 3 Examples of rater explanations for ratings of individual trials




Study criteria noted by raters that
training did not specifically address
Rating commentary
Eligibility: who is selected
to participate in the trial?
Participants essentially identical
to those who would receive
the intervention if it was in
usual care: both health care
systems and patients
Lots of exclusions (for example, those
who do not comply, respond to treatment,
or are not at high risk for primary outcome,
are children or elderly), or use many
selection tests not used in usual care.
Cognitive impairment; clinic size; clinic
willingness to participate; patient
willingness to consent
(more explanatory)
Differentiating site vs. patient eligibility
Especially for complex or novel interventions,
are exclusions based on comorbidities any
different for intervention than what would
occur in usual care?
Recruitment: how
are participants
recruited into the trial?
Usual appointment or clinic Targeted invitation letters, advertising in
newspapers, radio plus incentives and
other routes that would not be used in
usual care
Informed consent procedures; extra
screening procedures in EHR
(more explanatory)
None noted
Setting: where is the
trial being done?
Setting of trial identical to
usual care setting
A very explanatory approach would occur
only a single center, or only specialized
trial or academic centers
Diversity in terms of number, location,
and organization type considered in
very pragmatic ratings; regional studies,
studies conducted in one type of health
care system; consent requirements
considered in more explanatory ratings
There are many dimensions to consider
when comparing the setting to usual care.
For example, was the goal to rate compared
to a particular type of setting such as safety
net clinics or to include multiple types of
health systems? Additionally, participating
institutions tended to have good quality
improvement capacity; it is difficult to rate
how this compares to “typical” settings.
Organization: what
expertise and
resources are needed to
deliver the intervention?
Resources, provider expertise
and the organization of care
delivery in the intervention
arm identical to usual care
Trial increases staff levels, gives additional
training, requires more than usual
experience or certification and increases
resources
Space, intervention delivery, outreach
(more explanatory). A train the trainer
approach is one way to make training
procedures more pragmatic.
It was noted that many of these trials take
place in innovative health systems that may
not be typical of the country, potentially
conflating setting and organization.
Difficult to determine weight or importance
of organization at provider level versus
organization at IT or administration level.
The amount of effort undertaken to maintain
‘adherence’ at the organizational level was








If there is a strict protocol, monitoring
and measures to improve compliance,
with specific advice on allowed
co-interventions and complications
An example noted was that guidance
in place but provider can deviate from
it or the guidance can be modified over
time based on stakeholder feedback
What happens if there is a strict protocol in
usual care as well?
Flexibility of adherence:
what measures are in place
to make sure participants
adhere to the intervention?
No more than usual
encouragement to adhere
to the intervention
Exclusion based on adherence, and
measures to improve adherence if
found wanting
Distinguishing adherence encouragement
that would happen in usual care from the
intervention. At the clinic/provider level,
monitoring was interpreted to relate both




No more than usual follow-up More frequent, longer visits, unscheduled
visits triggered by primary outcome event
or intervening event, and more extensive
data collection
Use of electronic records (more
pragmatic); additional contacts,










Table 3 Examples of rater explanations for ratings of individual trials (Continued)
Primary outcome: how
relevant is it to participants?
Outcome measure very
relevant to participants
Using a surrogate, physiological outcome,
central adjudication or use assessment
expertise that is not available in usual care,
or the outcome is measured at an earlier
time than in usual care
Implementation feasibility or other
procedural details (more explanatory)
How to handle clinic- versus patient-relevant
outcomes
Primary analysis: to what
extent are all data
included?
intention to treat with all
available data
Excludes ineligible post-randomization
participants, includes only completers or
those following the treatment protocol
Extensive analytic details were not available









Raters struggled to use the PRECIS system for this
analysis, as illustrated by the comments in Table 3, PI
discussions, and the ICC range from 0.05 to 0.31. For
comparison, in a study by Glasgow et al., in which they
studied three effectiveness trials of weight loss in obese
patients with comorbid conditions [5], the ICC for indi-
vidual items was 0.72, and the overall kappa interrater
reliability on the composite PRECIS score was r = 0.88.
The large difference in interrater reliability is surprising
given that we used a similar training approach and had
access to detailed study information.
Whereas the rating challenges limit our ability to draw
conclusions about specific studies, some general obser-
vations emerge. Across studies and time points, the
domains rated as most pragmatic were analysis and re-
cruitment, whereas those that were closer to explanatory
(average range 3 to 4) were organization, delivery, and
adherence. This could reflect, in part, that it may be eas-
ier to be pragmatic for some domains than for others.
For example, it is relatively easy to be pragmatic for pa-
tient eligibility by taking all comers; but it is often diffi-
cult to be pragmatic when trying to deliver an
intervention.
It is important to note that explanatory elements of
pragmatic design do not necessarily relate to study qual-
ity. Some trial aspects may need to be designed in a
more explanatory manner in order to answer the study
question. PRECIS-2 ratings provide guidance to re-
searchers on the appropriate corresponding study proce-
dures. For example, the more explanatory rating of the
organization domain (how the resources, provider ex-
pertise and the organization of care delivery in the inter-
vention arm of the trial compare to usual care) indicates
that the study involves extra resources such as training.
By noting this during the design phase, study teams can
make sure they communicate with involved health sys-
tems about time and resource requirements. However, it
is important to note that requiring additional training
does not necessarily make the organizational domain
more explanatory: the same approaches to training
personnel to roll out a trial intervention could be the
same as those approaches used by the organization to
roll out a clinical or quality improvement intervention.
It is difficult to compare our overall findings to other
reports that rated studies using PRECIS domains be-
cause they utilized an earlier version of the tool and had
different study questions. However, one other study has
used PRECIS criteria to examine change over time. Elder
and Munk [10] used a modified PRECIS wheel to obtain
input on study methodology while planning a new phase
of research examining two complementary therapies for
chronic low back pain. The study led to re-evaluation of
the design of certain aspects, for example participant
characteristics, that were rated as more explanatory than
expected and could be made less restrictive. However, as
in our experience, the authors concluded that having a
more explanatory characteristic within a pragmatic trial
may be appropriate depending on the research question.
This study generated insights that may be useful for
future use or refinement of the PRECIS-2 tool. As per
Table 3, raters struggled with how to apply ratings. In
particular, comparing the intervention to usual care re-
quires guidance about 1) how to handle domains such as
recruitment that can pertain to health care settings or
patients; 2) how to rate a systems-change intervention
(which could become, but is not currently, standard
care) and 3) what level of existing supports/standards,
for example communication with leadership or use of
electronic health record functionality, is considered typ-
ical in usual care. After this study was completed, the
PRECIS-2 designers published a manuscript that fully
described the PRECIS-2 tool [3]. Their explanation of
the domains in detail highlights that the complexities we
encountered resonated with theirs, including how to rate
an intervention that is designed to change usual care
and how local care nuances (for example, data systems)
can influence ratings. The challenge of using the tool,
especially for some criteria, suggests that the PRECIS-2
criteria may need to be further refined in order to have
sufficient specificity to enable comparison of interven-
tion to usual care in the context of a broad range of set-
tings. The issue is not just tool development, but also
clarification of how we characterize care and what com-
ponents are “usual”. Having this more detailed under-
standing of usual care and guidance regarding how to
characterize care would enable a more clear understand-
ing of the degree to which the intervention differs from
usual care and has practical utility to a health system,
given the diversity of health systems that exist.
In addition, it would be helpful to have guidance about
the amount of study information that teams need in
order to best use the PRECIS-2 tool. If we had this guid-
ance, the benefit would be that all trials could more eas-
ily capture information. In turn, this would enable better
comparisons across trials and allow for analysis of a
broader trial portfolio. Additionally, looking across trials
and across time points would be useful, but we were
limited by what information we had. Therefore, provid-
ing guidance on what information is needed to best
apply this tool would better enable its utility.
The materials that we used to rate the study were the
grant application and progress report, which contained
many details that pertained to the PRECIS-2 domains but
were not organized according to PRECIS-2 domains. The
information in these documents may have contributed to
low interrater reliability; however, they contained a sub-
stantial amount of implementation-oriented information.
It is possible that ratings would have been even more
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difficult using the details typically available in a protocol
or manuscript of study findings. It also is possible that the
limited number of raters for each study could have con-
tributed to the low interrater reliability. However, in both
the Loudon et al. paper [3] and our experience, ratings ul-
timately benefited from local familiarity with the health
system where the trial was being conducted and direct in-
put from study team members helped prompt discussion
and clarification about study details. As such, we do not
necessarily see value in review by an external group, ex-
cept for providing advice about how to best use the
PRECIS-2 tool. The ability of the PRECIS-2 framework to
support discussions about how to interpret and
operationalize design decisions is helpful.
Conclusions
The raters participating in the process found it an inform-
ative way to learn about pragmatic design in general as
well as about specific studies. This study demonstrates
that PRECIS-2 can be used to rate protocols, as well as for
study planning, and helps address the need for systematic
approaches to reporting pragmatic studies [11]. However,
results of analyses using the criteria post hoc should factor
in the challenges encountered in our analysis. In addition,
refinements would be helpful for raters. These could in-
clude creating additional rating criteria, linked to numer-
ical rating, and exploring different formats for brief
training of raters. Our results highlight that researchers
should anticipate making changes to study protocols for
pragmatic trials based on health system realities.
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